Laser Corp. Announces FDA Clearance of the Q-LAS 10 Laser for Capsulotomies.Business Editors/Health & Medical Writers SALT LAKE CITY--(BUSINESS WIRE)--Oct. 17, 2000 Laser Corp. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :LSER LSER Linear Solvation Energy Relationship LSER Labor Standards Enforcement Report LSER London and South Eastern Railways (UK) ) Tuesday announced that the Q-LAS 10 has received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 510(K) clearance and the company will market this laser in the United States. This unique opthalmic laser, developed in cooperation with Haag-Streit AG, Switzerland, is used by the surgeon to perform posterior capsulotomies. The Q-LAS 10 is a Q-Switched YAG laser which is fully integrated into the arm of the slit lamp. This allows the surgeon to not only utilize the slit lamp for YAG laser treatments but also allows the use of the slit lamp as a standard examination unit. The integration of the YAG laser into a standard slit lamp is achieved without compromising its optical quality. B. Joyce Wickham, president and chief executive officer commented that, "With the addition of the Q-LAS 10 to the company's currently available medical products, the Nuvolase 532 for photocoagulation photocoagulation /pho·to·co·ag·u·la·tion/ (-ko-ag?u-la´shun) condensation of protein material by the controlled use of an intense beam of light (e.g. and the Dodick Laser PhotoLysis photolysis Breakdown of molecules into smaller units via absorption of light. Flash photolysis, an experimental technique developed by Manfred Eigen, Ronald George Weyford Norrish, and George Porter, studies short-lived chemical intermediates formed in many photochemical for cataract removal, the company now provides the opthalmologist with a full range of laser instruments for treatment of the most common eye disorders -- cataracts, secondary cataracts, glaucoma, and diabetic retinopathy. "Our first major opportunity to showcase these products since receiving FDA clearance will be at the upcoming meeting of the America Academy of Opthalmology, the largest annual meeting of opthalmologists. We anticipate sales of these products from this convention will be reflected in our fourth quarter results." The company is currently marketing and selling its opthalmic laser products through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , A.R.C. Laser Corp., Salt Lake City. Any statements released by Laser Corp. that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including economic, competitive, governmental, technological and other factors discussed in the company's filings with the Securities and Exchange Commission. Laser Corp., based in Salt Lake City, designs, manufactures, and markets opthalmic and cutaneous medical laser systems and industrial laser products. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion